Plain-English translation of NCT06990321 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether intermediate-dose cytarabine combined with venetoclax helps older adults with a serious blood cancer called acute myeloid leukemia (AML) stay cancer-free longer. You would only be eligible if you've already had initial chemotherapy that put your cancer into remission, and now doctors want to see if this combination medication can help keep it that way.
Older adults with intermediate or high-risk AML often have limited treatment options after their initial chemotherapy. This medication combination has shown promise, and this trial aims to understand how well it works specifically for older patients who have already achieved remission.
You likely qualify if…
You likely don't qualify if…
You would receive the combination medication as an outpatient, likely over several treatment cycles at the hospital or clinic. The study will collect information about your health, how you respond to the treatment, and any side effects you experience. The study will follow you from June 2025 through December 2026 with regular visits to monitor your blood work, organ function, and how well you're tolerating the medication.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China